截至2025年6月30日 13:30，上证科创板综合指数(000680)强势上涨1.51%，成分股翔宇医疗(688626)上涨 20.01%，华强科技(688151)上涨16.29%，晶品特装(688084)上涨15.29%，毕得医药(688073)，药康生物 (688046)等个股跟涨。科创综指ETF(589680)上涨1.56%，最新价报0.98元。 科创综指ETF(589680)，场外联接A：023757；联接C：023758；联接I：024141。 以上内容与数据，与有连云立场无关，不构成投资建议。据此操作，风险自担。 民生证券称，AI应用百花齐放，医疗、司法、金融、教育等具备广阔落地潜力。随着国产模型、国产 算力生态成熟，AI应用在多个垂直场景有望加速落地。以医疗为例，6月26日，蚂蚁集团推出全新的AI 健康应用"AQ"。基于蚂蚁的医疗大模型，AQ提供健康科普、就诊咨询、报告解读、健康档案等AI功 能，连接了全国超5000家医院、近百万医生、近200个名医AI分身等医疗服务。阿里、蚂蚁、字节、腾 讯等国内科技巨头纷纷入局，以模型能力为基石，联合拥有深刻行业Know-how的IT厂商，加速推进AI 应 ...

3 、 海康威视回应 " 被加拿大政府命令停止运营 " 称，强烈反对加拿大政府以所谓的 " 国家安全担忧 " 为由，作出海康威视加拿大公司在 120 天内关停的 决定。 这种做法罔顾事实，希望加拿大政府尊重法治，实事求是，而非以臆想和偏见为由采取歧视行动。此前，中国驻加拿大使馆发言人亦表示，中方 对此强烈不满和坚决反对。中方敦促加方停止把经贸问题政治化、泛安全化，停止对中国企业的无理打压，为中国企业正常经营提供公平、公正、非歧视 的环境。 1 、 6 月 28 日 -29 日， 2025 上市公司论坛在温州举行。论坛上，沪深北港四大交易所相关负责人集中发声，释放多维度改革信号。上交所副总经理王泊 表示，将扎实推进 "1+6" 改革举措和示范案例落实落地； 深交所副总经理李辉称，正紧锣密鼓地谋划和落实创业板改革；北交所副总经理周箴表示，将 守正创新，赋能中小企业高质量发展；港交所董事总经理徐经纬预计， "A+H" 上市趋势二季度越发明显，目前有超过 30 家 A 股企业已递交 H 股上市申 请，另有超过 20 家 A 股企业已发布关于 H 股上市计划的公告。 2 、海关总署公告称，在持续开展针对日本福岛核污染水 ...

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases.Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. 1. CertaraCertara (CERT -0.35%) is poised to capitalize on the transform ...

Core Viewpoint - The healthcare sector is positioned as a strong long-term investment opportunity, with a focus on companies that have shown adaptability and are well-prepared for future challenges [2]. Group 1: Abbott Laboratories - Abbott Laboratories, founded in 1888, has a market capitalization of $240 billion and offers diverse healthcare products across multiple sectors [4]. - The company is a leader in medical devices, diagnostics, nutritional products, and established pharmaceuticals, with notable products like the MitraClip and FreeStyle Libre [5][6]. - Abbott anticipates an 8% year-over-year revenue growth in 2025 and continues to innovate, recently receiving the European CE Mark for the Volt PFA System [7][8]. - Abbott has a strong dividend history, having increased its dividend for 53 consecutive years [8]. Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has a market capitalization of approximately $328 billion and generated $56.3 billion in sales last year [9][10]. - The company has successfully navigated the loss of U.S. exclusivity for its top product, Humira, by investing in R&D and acquisitions, leading to a robust product pipeline [11]. - AbbVie’s successors to Humira, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [12]. - AbbVie has increased its dividend by a cumulative 310% since its spin-off, with a forward dividend yield of 3.51% [12]. - The stock is considered relatively inexpensive, trading at 15.2 times forward earnings, with growth potential from new products [13].

Group 1 - ClearPoint Neuro's stock has faced pressure due to soft first-quarter results and additional capital raising, but strong consumables growth indicates underlying business progress [1] - System placements are highlighted as a positive aspect of ClearPoint's business performance [1] - Narweena, an asset manager, focuses on identifying market dislocations and believes in achieving excess risk-adjusted returns through secular growth opportunities in markets with barriers to entry [1] Group 2 - Narweena's research emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] - The aging population, low population growth, and stagnating productivity growth are expected to create new investment opportunities, differing from past trends [1] - Many industries may experience stagnation or secular decline, potentially improving business performance due to decreased competition [1] Group 3 - The economy is increasingly dominated by asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] - Richard Durant, the leader of Narweena, has a strong educational background in engineering, finance, and an MBA, along with passing the CFA exams [1]

I think I'm right in saying that in the context of robotics history, this was one of the top series Bees of All time. It's a significant sum of money. Let's start with what you're going to do with that funding and what you need to do to make progress.Right. Ed, first of all, thank you for having me. It's a pleasure to be here.What we're developing it for said, as you said, it's a robotic platform to tackle one of the biggest needs in medicine, which is the vision crisis. So currently today we have over 2 bi ...

Key Takeaways ALGN is expanding Invisalign with new products and international regulatory approvals. ALGN's iTero Lumina scanner gains traction with added restorative features and software upgrades. Align Technology has zero debt and strong cash flow, but forex pressures continue to impact revenues.Align Technology’s (ALGN) successful efforts to broaden the Invisalign business are poised to bring significant growth in the upcoming quarters. Also, iTero is gaining from the rapidly evolving intraoral scanni ...

Core Points - ReShape Lifesciences Inc. has regained compliance with Nasdaq's stockholders equity requirement, closing the listing matter [1][2] - The company previously faced potential delisting due to non-compliance with the minimum stockholders' equity requirement of $2.5 million [2] - As of March 31, 2025, the company's stockholders' equity was reported at $1.2 million [3] - The company raised a total of approximately $6.3 million through the sale of common stock in June 2025, which helped it regain compliance [3] Company Overview - ReShape Lifesciences is a leading company in weight loss and metabolic health solutions, offering a range of products and services for obesity and metabolic disease management [4] - The company provides the FDA-approved Lap-Band® System, which is a minimally invasive treatment for obesity [4] - Other offerings include an investigational vagal neuromodulation system for type 2 diabetes and metabolic disorders, and the non-surgical Obalon® balloon technology for weight loss [4]

Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands Autonomix’s growing global IP portfolio with over 80 issued patents THE WOODLANDS, TX, June 27, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced ...

Johnson & Johnson (JNJ -0.02%) is an iconic U.S. healthcare giant. It has changed over the years, but today its focus is on pharmaceuticals and medical devices. And it is an industry leader in both spaces. There are a lot of positives with J&J, as it is more commonly known on Wall Street, but there's one dark cloud that I can't ignore. And the shadow from that cloud is why I just can't justify buying Johnson & Johnson today.Why Johnson & Johnson is a great companyWhen I look for stocks, I generally start wi ...